Main Page

Neoplasm.org - An Open Hematology/Oncology Reference

Neoplasm.org is a collaborative, open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens. Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.

Quick links to major topic areas
Solid Tumors	Malignant Hematology

Links to all main disease pages

Solid Tumors
Breast Oncology
Early breast cancer (EBC)
EBC, NOS	HR-positive EBC	HER2-positive EBC	HER2-low EBC
HR-positive and HER2-positive EBC	Early triple-negative breast cancer (eTNBC)
Metastatic breast cancer (MBC)
MBC, NOS	HR-positive MBC	HER2-positive MBC	HER2-low MBC
HR-positive and HER2-positive MBC	Metastatic triple-negative breast cancer (mTNBC)	CNS metastases
Breast cancer with molecular alterations
BRCA-mutated Breast cancer	PI3K pathway-altered Breast cancer
Dermatologic Oncology
Melanoma
Melanoma, NOS	BRAF-mutated Melanoma	KIT-mutated Melanoma	NRAS-mutated Melanoma
Uveal melanoma
Non-melanoma skin cancer (NMSC)
Cutaneous BCC	Cutaneous SCC	Merkel cell carcinoma (MCC)
Endocrine Oncology
Other endocrine cancers
Adrenocortical carcinoma	Neuroendocrine tumor (NET)	Neuroendocrine carcinoma (NEC)	Pancreatic NET
Pheochromocytoma
Thyroid cancer without molecular alterations
Thyroid cancer, NOS	Anaplastic thyroid cancer (ATC)	Differentiated thyroid cancer (DTC)	Medullary thyroid cancer (MTC)
Thyroid cancer with molecular alterations
BRAF-mutated Thyroid cancer	RET-positive Thyroid cancer
Gastrointestinal Oncology
Upper GI tract
Esophageal cancer, NOS	Esophageal adenocarcinoma	Esophageal squamous cell carcinoma (ESCC)	Gastric cancer, NOS
HER2-positive gastric cancer
Lower GI tract
Anal cancer	Appendiceal tumor	Colon cancer, NOS	RAS wild-type colon cancer
Colorectal cancer (CRC), NOS	BRAF-mutated CRC	HER2-positive CRC	MSI-H or dMMR CRC
RAS wild-type CRC	Rectal cancer	Small bowel adenocarcinoma
Hepatobiliary cancer
Biliary tract cancer	Cholangiocarcinoma	Gallbladder cancer	Hepatocellular carcinoma (HCC)
Periampullary adenocarcinoma
Pancreatic cancer
Pancreatic adenocarcinoma, NOS	BRCA-mutated Pancreatic adenocarcinoma	NRG1-positive Pancreatic adenocarcinoma	Pancreatic NET

Malignant Hematology
Acute leukemias
Acute leukemia, KMT2A-rearranged	Acute myeloid leukemia (AML)	AML, FLT3-positive	AML, IDH-mutated
AML, NPM1-mutated	Acute promyelocytic leukemia (APL)	B-cell acute lymphoblastic leukemia (B-ALL)	B-ALL, Ph+
T-cell acute lymphoblastic leukemia (T-ALL)	Blastic plasmacytoid dendritic cell neoplasm (BPDCN)	CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myeloid leukemia (CML)	Chronic myelomonocytic leukemia (CMML)	Essential thrombocythemia (ET)	Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome (MDS)	Primary & secondary myelofibrosis (PMF/SMF)	Myeloproliferative neoplasm, accelerated phase (MPN-AP) New	Polycythemia vera (PV)
Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL)	Classical Hodgkin lymphoma (cHL)	CNS lymphoma	Diffuse large B-cell lymphoma (DLBCL)
Gastric DLBCL New	High-grade B-cell lymphoma (HGBL)	HIV-associated lymphoma	Mantle cell lymphoma (MCL)
Mediastinal gray-zone lymphoma (MGZL)	Primary mediastinal B-cell lymphoma (PMBL)	Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL)	Follicular lymphoma (FL)	Hairy cell leukemia (HCL)	NLP-HL
Indolent lymphoma (iNHL)	MALT lymphoma	Marginal zone lymphoma (MZL)	Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis	Multiple myeloma (main page)	MM induction	MM consolidation & maintenance
MM relapsed/refractory	Plasma cell leukemia (PCL)	POEMS syndrome	Smoldering multiple myeloma (SMM)
Disease-agnostic
FGFR1 New

Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.

Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.

Priorities of this project include: <section begin=goals />

• Creating a database of all approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology.
• Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature.
• Sample order sets and examples of supportive medications used with treatment regimens
• Aggregating useful links to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
• Creating, maintaining, and disseminating a formalized ontology of anticancer drugs and regimens.

<section end=goals />

Additional possibilities for this project may include:

• Creating synopses of pivotal clinical trials and regimens
• Prioritizing regimens by their efficacy and/or toxicity
• Capturing historical regimens that were standard-of-care prior to 2005
• Checklists for common clinical scenarios/diseases
• Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.

<inputbox> type=create width=70 placeholder=Type the name of the page you want to create break=no </inputbox>